

Ming-Ming He

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9434529/publications.pdf>

Version: 2024-02-01

33
papers

1,475
citations

516710

16
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

2335
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of <i>POLE</i> and <i>POLD1</i> Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. <i>JAMA Oncology</i> , 2019, 5, 1504.	7.1	287
2	CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. <i>Oncogene</i> , 2018, 37, 6025-6040.	5.9	211
3	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. <i>BMC Cancer</i> , 2015, 15, 350.	2.6	126
4	Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. <i>Nature Communications</i> , 2020, 11, 1507.	12.8	121
5	Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. <i>Annals of Translational Medicine</i> , 2019, 7, 640-640.	1.7	103
6	Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. , 2019, 7, 264.		66
7	microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. <i>Oncotarget</i> , 2015, 6, 10868-10879.	1.8	64
8	Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. <i>Cancer Letters</i> , 2020, 473, 74-89.	7.2	63
9	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	6.5	49
10	Immune-Mediated Diseases Associated With Cancer Risks. <i>JAMA Oncology</i> , 2022, 8, 209.	7.1	48
11	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 1879-1887.	1.8	33
12	Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank. <i>International Journal of Cancer</i> , 2021, 148, 1867-1878.	5.1	33
13	Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. <i>BMC Cancer</i> , 2019, 19, 460.	2.6	30
14	The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e83921.	2.5	27
15	S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e82798.	2.5	23
16	The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. <i>Oncotarget</i> , 2016, 7, 75094-75103.	1.8	23
17	Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 2342.	12.8	21
18	Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. <i>Cancer Science</i> , 2018, 109, 3575-3582.	3.9	19

#	ARTICLE	IF	CITATIONS
19	Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 805-811.	4.9	18
20	Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. <i>Gut</i> , 2022, 71, 1340-1349.	12.1	17
21	Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. <i>PLoS ONE</i> , 2014, 9, e89965.	2.5	17
22	Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. <i>Medical Oncology</i> , 2016, 33, 122.	2.5	16
23	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. <i>Oncotarget</i> , 2016, 7, 28356-28368.	1.8	16
24	Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy. <i>Journal of Cancer</i> , 2018, 9, 660-666.	2.5	11
25	The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching. <i>Journal of Cancer</i> , 2019, 10, 602-610.	2.5	10
26	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	5.9	8
27	<p>>A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients</p>>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3993-4003.	1.9	4
28	Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 264.	3.3	3
29	Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 69-79.	2.3	3
30	Gallstone Disease and Risk of Conventional Adenomas and Serrated Polyps: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2346-2349.	2.5	3
31	Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16022-e16022.	1.6	1
32	A phase I study of SHR7390 plus camrelizumab in advanced/metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15553-e15553.	1.6	1
33	Mutational profiles of sporadic synchronous colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15555-e15555.	1.6	0